Therapeutics and Clinical Risk Management
Scope & Guideline
Unlocking the potential of safe and effective medication practices.
Introduction
Aims and Scopes
- Therapeutic Innovations and Evaluations:
The journal publishes studies that explore new therapeutic modalities, drug efficacy, and safety profiles, ensuring that healthcare professionals are informed about the latest advancements in treatment options. - Clinical Risk Assessment and Management:
Research focusing on identifying and mitigating clinical risks, including adverse events and complications associated with medical interventions, is a core area of the journal. - Patient-Centric Care Strategies:
The journal emphasizes studies that evaluate patient outcomes, quality of life, and the impact of therapeutic approaches on patient populations, reflecting a commitment to patient-centered healthcare. - Evidence-Based Medicine and Guidelines:
Publications often include systematic reviews, meta-analyses, and guideline development to support evidence-based practice in clinical settings. - Interdisciplinary Research:
The journal encourages interdisciplinary studies that integrate pharmacology, surgery, nursing, and public health perspectives to address complex clinical challenges.
Trending and Emerging
- Integration of Machine Learning and AI in Healthcare:
Recent studies increasingly focus on the application of machine learning algorithms to predict clinical outcomes and enhance decision-making processes in patient management. - Personalized and Precision Medicine:
There is a growing emphasis on research that tailors therapeutic interventions to individual patient profiles, particularly in oncology, cardiology, and chronic disease management. - Telemedicine and Digital Health Solutions:
The rise of telehealth has led to a surge in studies evaluating its effectiveness, patient satisfaction, and impact on healthcare delivery, especially post-COVID-19. - Multidisciplinary Approaches to Complex Conditions:
Research incorporating multidisciplinary teams to manage complex health conditions is gaining traction, reflecting the complexity of modern healthcare needs. - Patient Safety and Quality Improvement Initiatives:
An increasing number of publications are dedicated to strategies for enhancing patient safety and quality of care in clinical settings, indicating a heightened focus on risk management.
Declining or Waning
- Traditional Pharmacological Approaches:
There has been a noticeable decrease in studies solely focused on traditional pharmacological treatments, possibly due to a growing interest in personalized medicine and novel therapeutic approaches. - Single-Modal Interventions:
Research concentrating on isolated treatment modalities without considering comprehensive care strategies is less prevalent, indicating a trend towards more integrative and holistic approaches. - Longitudinal Studies in Chronic Conditions:
The frequency of longitudinal studies examining chronic disease management has waned, possibly due to challenges in funding and patient retention, leading to fewer insights into long-term therapeutic effectiveness. - Basic Science Research:
Basic science studies that do not directly translate to clinical applications appear to be declining, as the journal prioritizes research with immediate relevance to clinical practice. - Low-Risk Surgical Interventions:
There is a diminishing number of publications focused on low-risk surgical procedures, as the journal seems to be shifting towards high-impact clinical studies with significant implications for patient outcomes.
Similar Journals
Clinical Pharmacology-Advances and Applications
Empowering Research for Better Patient OutcomesClinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Advancing pharmacological knowledge for better health outcomes.FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Pioneering research for a healthier cardiovascular future.JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.
International Journal of Pharmacology
Empowering Scholars to Shape the Future of PharmacologyWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Empowering researchers and practitioners with open-access insights.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.
Drug Healthcare and Patient Safety
Championing safe medication practices for all.Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.
JOURNAL OF CLINICAL PHARMACOLOGY
Exploring the Frontiers of Pharmacological ResearchWelcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.
ANNALS OF PHARMACOTHERAPY
Exploring Innovations in Therapeutic ScienceANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.
CLINICAL THERAPEUTICS
Pioneering the future of drug development and clinical practice.Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.
Acta Facultatis Medicae Naissensis
Exploring the Frontiers of Health SciencesActa Facultatis Medicae Naissensis is an esteemed open-access journal published by the University of Niš, Faculty of Medicine, situated in Serbia. Since its inception in 2009, this journal has been a vital platform for the dissemination of innovative research findings in the field of Medicine, particularly focusing on miscellaneous areas within the discipline. With an ISSN of 0351-6083 and an E-ISSN of 2217-2521, it operates under a commitment to free accessibility, enhancing visibility for authors and readers alike since 2012. In the 2023 categorization, it holds a respectable Q4 ranking in Medicine (Miscellaneous) and positions itself at the 34th percentile among general medicine publications in Scopus, reflecting its growing academic impact. Researchers, professionals, and students seeking an interactive scholarly exchange in medicine will find Acta Facultatis Medicae Naissensis a rich resource, contributing significantly to the understanding of health sciences and clinical practice through its diverse range of articles.